{"filing":{"accession_number":"0001213900-26-082101","cik":"0001949257","ticker":"RDPTF","company_name":"Radiopharm Theranostics Ltd","form":"6-K","filing_date":"2026-07-28","report_date":"2026-07-28","primary_document":"ea0299455-6k_radiopharm.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1949257/000121390026082101/ea0299455-6k_radiopharm.htm"},"events":[{"id":20986,"run_id":18908,"accession_number":"0001213900-26-082101","anchor_item_number":"EX-99.1","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"The exhibit announces the closing of a registered direct offering of 1,281,646 ADSs (representing 384,493,800 ordinary shares) at US$3.16 per ADS, raising approximately US$4.1 million in gross proceeds. The offering also includes concurrent private placement of unregistered warrants to purchase additional ADSs, plus a separate Australian private placement and Share Purchase Plan. This is a material dilutive equity issuance by a clinical-stage biopharmaceutical company raising capital through registered and unregistered securities offerings.","company_name":"Radiopharm Theranostics Ltd","ticker":"RDPTF","filing_date":"2026-07-28","form":"6-K","submitted_at":null,"items":[{"id":20508,"accession_number":"0001213900-26-082101","item_number":"EX-99.1","item_title":"ea029945501ex99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The exhibit announces the closing of a registered direct offering of 1,281,646 ADSs (representing 384,493,800 ordinary shares) at US$3.16 per ADS, raising approximately US$4.1 million in gross proceeds. The offering also includes concurrent private placement of unregistered warrants to purchase additional ADSs, plus a separate Australian private placement and Share Purchase Plan. This is a material dilutive equity issuance by a clinical-stage biopharmaceutical company raising capital through registered and unregistered securities offerings.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-28T16:00:40.820616+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":20508,"accession_number":"0001213900-26-082101","item_number":"EX-99.1","item_title":"ea029945501ex99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The exhibit announces the closing of a registered direct offering of 1,281,646 ADSs (representing 384,493,800 ordinary shares) at US$3.16 per ADS, raising approximately US$4.1 million in gross proceeds. The offering also includes concurrent private placement of unregistered warrants to purchase additional ADSs, plus a separate Australian private placement and Share Purchase Plan. This is a material dilutive equity issuance by a clinical-stage biopharmaceutical company raising capital through registered and unregistered securities offerings.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-28T16:00:40.820616+00:00","company_name":"Radiopharm Theranostics Ltd","ticker":"RDPTF","filing_date":"2026-07-28"}]}